Citations

Clear

13603 citation(s) found for "_, _".

Extracorporeal Membrane Oxygen Assisted Intubation for Complex Airways
Bhalerao, R A, Hinni, Michael L., Bhalerao, Ritu V , Sell‐Dottin, Kristen , Chang, Brent A.

Mayo Clinic

Ear, Nose & Throat Journal | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/01455613251368709 | PMID 40832957 Get It

Objective: Airway management in patients with severely-narrowed tracheal lumens presents significant challenges, especially when traditional intubation methods are not feasible. In such cases, failed intubation attempts can worsen airway compromise and cause life-threatening complications. Extracorporeal membrane oxygenation (ECMO) offers an alternative approach to ensure oxygenation and ventilation during complex airway surgeries. The objective of this study was to assess the safety and feasibility of using venovenous ECMO to ensure oxygenation before attempting intubation in patients with severely-narrowed tracheal lumens undergoing head and neck surgery. Methods: This is a retrospective case series of 3 adult patients who underwent venovenous ECMO-assisted intubation for head and neck surgeries at a single institution between 2010 and 2023. The primary outcome was the successful establishment of an airway and the avoidance of respiratory failure during the surgical procedure. Results: All 3 patients successfully underwent ECMO-assisted intubation. None of the patients experienced major complications directly attributable to ECMO, and all were extubated within 24 hours postoperatively. Conclusions: Venovenous ECMO provides an effective strategy for managing difficult airways in patients with severely-narrowed tracheas, enabling safe anesthesia induction. This technique may be crucial in preventing complications associated with traditional airway management methods.
Detection, quantitation, and genotyping of human papillomavirus circulating tumor DNA by droplet digital PCR
Fernholz, Emily C. , Abel, Kathryn M. Van , Moore, Eric J. , Daniel, Jeannie, Hunter, Danielle E., Lewis, James S. , Wendlandt, Erik, Binnicker, Matthew J. , Bartemes, Kathleen R. , Binnicker, Matthew J , Van Abel, Kathryn M , Routman, David M. , Ma, Daniel J.

Mayo Clinic

Journal of Clinical Microbiology | August 19, 2025 | Volume: 63 | Issue: 9 | Pages: No page available

10.1128/jcm.00585-25 | PMID 40827899 Get It

ABSTRACT Human papillomavirus (HPV) is comprised of >200 genotypes and has an ~8 kb, circular, double-stranded DNA genome. Transmission of HPV occurs through skin-to-skin contact and infection of squamous epithelial cells of cutaneous and mucosal surfaces. HPV genotypes are categorized as low- or high-risk (hrHPV) based on oncogenic potential. There are approximately 14 types of hrHPV that can cause several types of cancer, including HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC). Detection of HPV(+)OPSCC is traditionally accomplished using p16 immunohistochemistry (IHC) and HPV-specific testing, either DNA or RNA in situ hybridization (ISH) staining or DNA-based PCR of suspected tumor biopsy tissue. More recently, platelet-poor plasma (PPP) samples from patients with HPV(+)OPSCC have proven useful for detection and quantitation of fragments of HPV circulating tumor DNA (ctDNA). ctDNA has been shown to be useful in determining treatment response and monitoring for disease recurrence. In this study, a novel droplet digital PCR assay (ddPCR) was developed and validated for the detection and quantitation of ctDNA from 5 hrHPV genotypes in PPP. Analytical sensitivity ranged from 7.71 to 19.45 fragments of HPV ctDNA per milliliter of PPP across five hrHPV genotypes. In patients with confirmed primary or recurrent HPV(+)OPSCC or HPV(-)OPSCC, testing of corresponding PPP samples ( n = 32) by ddPCR demonstrated 90.63% (29/32) overall agreement with p16/HPV-ISH biopsy results. Compared with reference ddPCR assays performed at outside laboratories, our ddPCR assay yielded 90% (9/10) overall agreement. This assay may provide clinicians with a tool for monitoring HPV ctDNA prior to, during, and after treatment of an HPV-associated cancer. IMPORTANCE At least 14 genotypes of human papillomavirus (HPV) have been identified to have high oncogenic potential. While molecular diagnostic testing for HPV is widely available for liquid cytologic cervical samples, testing is limited for other sample types, including liquid biopsy samples, such as platelet-poor plasma (PPP). With the rising incidence of HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC), laboratory testing is an essential part of patient diagnosis, management, and surveillance. Here, we summarize the development and analytical performance validation of a multiplexed, droplet digital PCR (ddPCR) assay for the detection and quantitation of HPV circulating tumor DNA (ctDNA) in PPP. This assay may provide clinicians with a tool to address minimal residual disease for patients with an HPV-associated cancer.
Artificial Intelligence-Guided Neuromodulation in Heart Failure with Preserved and Reduced Ejection Fraction: Mechanisms, Evidence, and Future Directions
Ansari, Rabiah Aslam, Senapati, Sidhartha Gautam , Ahluwalia, Vibhor, Panjwani, Gianeshwaree Alias Rachna , Kaur, Anmolpreet , Yerrapragada, Gayathri, Kala, Jayavinamika Jayapradhaban, Poonguzhali, E. , Karuppiah, Shiva Sankari, Asadimanesh, Naghmeh, Muthyala, Anjani, Arunachalam, Shivaram P. , Kaur, Anmolpreet , Jayapradhaban Kala, Jayavinamika, Arunachalam, S P , Panjwani, Gianeshwaree Alias Rachna , Ansari, Rabiah Aslam

Mayo Clinic

Journal of Cardiovascular Development and Disease | August 19, 2025 | Volume: 12 | Issue: 8 | Pages: 314

10.3390/jcdd12080314 | PMID 40863380 Get It

Heart failure, a significant global health burden, is divided into heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), characterized by systolic dysfunction and diastolic stiffness, respectively. While HFrEF benefits from pharmacological and device-based therapies, HFpEF lacks effective treatments, with both conditions leading to high rehospitalization rates and reduced quality of life, especially in older adults with comorbidities. This review explores the role of artificial intelligence (AI) in advancing autonomic neuromodulation for heart failure management. AI enhances patient selection, optimizes stimulation strategies, and enables adaptive, closed-loop systems. In HFrEF, vagus nerve stimulation and baroreflex activation therapy improve functional status and biomarkers, while AI-driven models adjust stimulation dynamically based on physiological feedback. In HFpEF, AI aids in deep phenotyping to identify responsive subgroups for neuromodulatory interventions. Clinical tools support remote monitoring, risk assessment, and symptom detection. However, challenges like data integration, ethical oversight, and clinical adoption limit real-world application. Algorithm transparency, bias minimization, and equitable access are critical for success. Interdisciplinary collaboration and ethical innovation are essential to develop personalized, data-driven, patient-centered heart failure treatment strategies through AI-guided neuromodulation.
Diagnostic Utility of PRAME in Rare Melanoma Mimics: A Comparative Analysis Including GNET, MMNST, Epithelioid MPNST, and MITF‐Rearranged Melanocytic Tumors
Shah, Ahmed , Molligan, Jeremy , Dehner, Carina , Torres‐Mora, Jorge , Shah, Ahmed , Molligan, Jeremy F , Dehner, Carina A , Shah, Ahmed

Mayo Clinic

Journal of Cutaneous Pathology | August 18, 2025 | Volume: 52 | Issue: 11 | Pages: 710-719

10.1111/cup.14849 | PMID 40819908 Get It

ABSTRACTBackgroundDifferentiating metastatic melanoma from histologic mimics such as malignant gastrointestinal neuroectodermal tumor (GNET), malignant melanotic nerve sheath tumor (MMNST), and epithelioid malignant peripheral nerve sheath tumor (EMPNST) poses significant diagnostic challenges due to overlapping morphology and immunophenotypes. PRAME is a novel immunohistochemical marker increasingly used to distinguish melanoma from its mimics, but remains underexplored in these rare tumor types.MethodsPRAME immunohistochemistry was performed on four GNETs, seven MMNSTs, 10 EMPNSTs, 16 metastatic melanomas (including eight undifferentiated melanomas), and two MITF‐rearranged melanocytic tumors. PRAME expression was scored from 0 to 4+ based on the percentage of tumor nuclei showing moderate to strong staining.ResultsAll GNETs, MMNSTs, and MITF‐rearranged tumors were PRAME‐negative. EMPNSTs showed variable expression: six were negative (0–1), one equivocal (2+), and three positive (3–4+). Fifteen of 16 melanomas were PRAME‐positive. PRAME scores differed significantly among tumor types (p = 1.99 × 10−5). PRAME demonstrated high sensitivity and specificity for distinguishing metastatic melanoma from primary mimickers including GNET and MMNST, but low specificity in EMPNST (71.4%).ConclusionsPRAME reliably distinguishes metastatic melanoma from GNET and MMNST, supporting its use in this differential. However, its reduced specificity in EMPNST limits its standalone diagnostic value in this context, emphasizing the need for a multimodal approach.
GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis
Wu, Jiao , Cheng, Alice, Harris, Peter C. , Zhou, Julie , Cheng, Alice Shasha, Zhou, Julie Xia, Harris, Peter C , Weimbs, Thomas , Li, Xiaogang

Mayo Clinic

The FASEB Journal | August 15, 2025 | Volume: 39 | Issue: 16 | Pages: No page available

10.1096/fj.202501605r | PMID 40815122 Get It

ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) are a class of medications that mimic the actions of the hormone GLP‐1, conferring beneficial effects on weight management and other metabolic conditions. However, whether GLP‐1RA plays a kidney‐protective action in ADPKD remains unknown. In this study, we define the role and mechanisms of one of the most popular GLP‐1RA agonists, Semaglutide, in ADPKD. We show that the expression of GLP‐1R is decreased in Pkd1 mutant renal epithelial cells and kidneys. Treatment with Semaglutide delays cyst growth in aggressive and long‐lasting Pkd1 mutant mouse models. Treatment with Semaglutide (1) decreases glucose uptake, ATP generation, and glycolysis, (2) deactivates PKD‐associated signaling pathways, including Rb, S6, and Stat3, resulting in a decrease in cell proliferation, (3) deactivates NF‐kB signaling pathways, resulting in a decrease in the expression of cytokines and the recruitment of macrophages, (4) normalizes mitochondrial morphology and function, (5) induces Pkd1 mutant renal epithelial cell death, (6) induces ketosis characterized by an increase in serum level of beta‐hydroxybutyrate (BHB) and the activation of AMPK, and (7) alleviates renal fibrosis through deactivation of TGF‐b signaling in Pkd1 mutant mouse kidneys. This study highlights the potential of GLP‐1R agonists as a novel therapeutic strategy for ADPKD treatment.
Beyond Post hoc Explanations: A Comprehensive Framework for Accountable AI in Medical Imaging Through Transparency, Interpretability, and Explainability
Singh, Yashbir , Hathaway, Quincy A. , Keishing, Varekan, Salehi, Sara , Wei, Yujia , Vera-Garcia, Diana V. , Kh, Almurtadha Mula, Quaia, Emilio , Vera-Garcia, Diana V , Quaia, Emilio , Andersen, Jesper B , Singh, Yashbir , Hathaway, Quincy A , Salehi, Sara , Wei, Yujia , Horvat, Natally , Choudhary, Ashok, Andersen, Jesper B.

Mayo Clinic

Bioengineering | August 15, 2025 | Volume: 12 | Issue: 8 | Pages: 879

10.3390/bioengineering12080879 | PMID 40868392 Get It

The integration of artificial intelligence (AI) in medical imaging has revolutionized diagnostic capabilities, yet the black-box nature of deep learning models poses significant challenges for clinical adoption. Current explainable AI (XAI) approaches, including SHAP, LIME, and Grad-CAM, predominantly focus on post hoc explanations that may inadvertently undermine clinical decision-making by providing misleading confidence in AI outputs. This paper presents a systematic review and meta-analysis of 67 studies (covering 23 radiology, 19 pathology, and 25 ophthalmology applications) evaluating XAI fidelity, stability, and performance trade-offs across medical imaging modalities. Our meta-analysis of 847 initially identified studies reveals that LIME achieves superior fidelity (0.81, 95% CI: 0.78–0.84) compared to SHAP (0.38, 95% CI: 0.35–0.41) and Grad-CAM (0.54, 95% CI: 0.51–0.57) across all modalities. Post hoc explanations demonstrated poor stability under noise perturbation, with SHAP showing 53% degradation in ophthalmology applications (ρ = 0.42 at 10% noise) compared to 11% in radiology (ρ = 0.89). We demonstrate a consistent 5–7% AUC performance penalty for interpretable models but identify modality-specific stability patterns suggesting that tailored XAI approaches are necessary. Based on these empirical findings, we propose a comprehensive three-pillar accountability framework that prioritizes transparency in model development, interpretability in architecture design, and a cautious deployment of post hoc explanations with explicit uncertainty quantification. This approach offers a pathway toward genuinely accountable AI systems that enhance rather than compromise clinical decision-making quality and patient safety.
Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline
Agarwal, Arnav , Manja, Veena , Agoritsas, Thomas , MacDonald, Helen, Li, Sheyu , Rodríguez‐Gutiérrez, René , Heen, Anja Fog , Gabi, Jenan, Jeppesen, Britta Tendel, Jha, Vivekanand , Nagler, Evi, Odom, Adrienne, Rodondi, Nicolas, Wright, Robin, Vandvik, Per Olav , Agarwal, Arnav , Li, Sheyu , Mustafa, Reem A , Macdonald, Helen, Foroutan, Farid , Rayner, Daniel , Åsvold, Bjørn Olav , Guo, Lixin , Hao, Qiukui , Jeppesen, Britta Tendal, Rodondi, Nicolas , Shetty, Sahana , Vermandere, Mieke , Guyatt, Gordon

Mayo Clinic

BMJ | August 15, 2025 | Volume: 390 | Issue: No issue available | Pages: e082071

10.1136/bmj-2024-082071 | PMID 40813129 Get It

Abstract Clinical question What are the benefits and harms of medications for adults with type 2 diabetes at varied risks of cardiovascular and kidney related complications? Context Emerging clinical trials of novel medications have demonstrated benefits on cardiovascular, kidney, and weight related outcomes in people with type 2 diabetes. Dynamically updated practice guidelines adhering to standards of trustworthiness are necessary in response to a rapidly evolving evidence base and the availability of multiple medication alternatives. This living practice guideline incorporates the latest available medications and evidence and provides recommendations stratified by risks of cardiovascular and kidney complications to inform diabetes management. Recommendations The panel issued risk-stratified recommendations regarding four prioritised medications for adults with type 2 diabetes (SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone and tirzepatide): • Lower risk (three or fewer cardiovascular risk factors without established cardiovascular disease (CVD) or chronic kidney disease (CKD)): weak recommendation against SGLT-2 inhibitors or GLP-1 receptor agonists. • Moderate risk (more than three cardiovascular risk factors without established CVD or CKD; or established CVD and/or CKD at lower risk of complications): weak recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation against finerenone in adults with CKD. • Higher risk (established CVD and/or CKD at higher risk of complications, or established heart failure): strong recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation in favour of finerenone in adults with CKD. • Across risk strata: weak recommendation in favour of tirzepatide in adults with obesity. About this guideline and how it was created An international panel including two patient partners, clinicians, and methodologists produced these recommendations. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits, harms and burdens of treatment from an individual patient perspective. Recommendations were informed by a linked living systematic review and network meta-analysis evaluating relative benefits and harms updated to 31 July 2024; and by linked systematic reviews addressing risk prediction models and values and preferences of adults with type 2 diabetes. Candidate therapeutics are prioritised based on availability of sufficient randomised trial data, relevance to a global audience and likelihood of changing practice. This is the first version of the living guideline. The guideline is part of the BMJ Rapid Recommendations series. MAGICapp displays the most recent version of the guideline and full content including evidence summaries and decision aids; major updates will be published in The BMJ . We encourage re-use, adaptation and translation of these living guidelines, and recognise that the lack of availability or high costs of some medications may be prohibitive and will impact on how these recommendations are implemented across different health care systems.
Restless Legs Syndrome, Periodic Leg Movements, Hypertension and Cardiovascular Diseases
Dauvilliers, Yves , Chenini, Sofiène , Barateau, Lucie , Somers, Virend K. , Somers, Virend K. , Dauvilliers, Yves

Mayo Clinic

Circulation Research | August 14, 2025 | Volume: 137 | Issue: 5 | Pages: 746-763

10.1161/circresaha.125.325677 | PMID 40811502 Get It

Restless legs syndrome (RLS) is a frequent sleep-related sensorimotor disorder defined by an urge to move the legs in the evening while resting. Severe RLS symptoms can negatively impact sleep, mood, and quality of life. Periodic leg movements during sleep and wakefulness are found in 60% to 80% of patients with RLS. The pathophysiology of RLS and periodic leg movement is still poorly understood and involves brain iron deficiency, dopamine dysregulation, and genetic predisposition. Over the past decades, several cross-sectional and longitudinal studies have reported an association between RLS, cardiovascular disease, and hypertension although the magnitude, direction, and underlying mechanisms of these associations remain inconclusive. Periodic leg movements during sleep are concomitant with an increase in blood pressure and heart rate, which may affect the physiological nocturnal blood pressure dip and, therefore, lead to an increased incidence of cardiovascular disease. Insomnia and sleep deprivation linked to sensory discomfort could also increase the sympathetic tone and contribute to an increase in cardiovascular risk. Comorbidities and associated sleep disorders may also synergically increase cardiovascular risk. This narrative review details the current knowledge of RLS, a still underdiagnosed and poorly recognized disorder, and examines the epidemiological relationship between RLS, cardiovascular disease and hypertension, potential mechanisms underlying this association, and strategies to reduce the risk of cardiovascular disease in patients with moderate-to-severe RLS. Greater multidisciplinary collaborations between cardiologists and sleep specialists are needed to better identify, understand, and manage patients with sleep disorders, including those with RLS.
Obstructive Sleep Apnea and Cardiometabolic Disease: Obesity, Hypertension, and Diabetes
Tasali, Esra , Pamidi, Sushmita , Covassin, Naima , Somers, Virend K. , Somers, Virend K.

Mayo Clinic

Circulation Research | August 14, 2025 | Volume: 137 | Issue: 5 | Pages: 764-787

10.1161/circresaha.125.325676 | PMID 40811500 Get It

Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder, characterized by recurrent upper airway obstruction during sleep, resulting in intermittent hypoxia, increased sympathetic activation, and sleep deficiency. Over the past 2 decades, there has been a robust body of evidence to support a strong link between OSA and cardiometabolic diseases. Obesity is an important risk factor for OSA. Observational studies indicate that OSA is a strong risk factor for the development of hypertension and diabetes. Moreover, clinical and experimental studies support a causal role of OSA in hypertension and impairments in glucose metabolism, beyond excess weight. Notably, OSA is particularly underdiagnosed and undertreated in women, which may heighten the cardiometabolic risk. OSA is often overlooked during pregnancy and has been linked to adverse cardiometabolic outcomes in observational studies. In randomized clinical trials, treatment of OSA with continuous positive airway pressure reduces blood pressure in individuals with hypertension, but the beneficial effects of continuous positive airway pressure on glycemic outcomes are less convincing. Inconsistent cardiometabolic response to OSA treatment can be partly explained by failure to consider heterogeneity in OSA and variable continuous positive airway pressure adherence among diverse populations. In this review, we summarize the relationships between OSA and cardiometabolic conditions with a particular focus on obesity, hypertension, and diabetes. We review the current knowledge on the heterogeneity in OSA and discuss potential underlying mechanisms for impairments in blood pressure and glucose metabolism in OSA. We also provide a clinical perspective for OSA management considering current research gaps and emerging approaches for the prevention and treatment of cardiometabolic disease.
Sleep Disruption and Atrial Fibrillation: Evidence, Mechanisms and Clinical Implications
Deshmukh, Abhishek , Covassin, Naima , Dauvilliers, Yves , Somers, Virend K. , Somers, Virend K. , Dauvilliers, Yves

Mayo Clinic

Circulation Research | August 14, 2025 | Volume: 137 | Issue: 5 | Pages: 788-808

10.1161/circresaha.125.325612 | PMID 40811503 Get It

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, with its incidence rising due to aging populations, obesity, and advancements in diagnostic modalities. The interplay between sleep disorders and AF is increasingly recognized, with obstructive sleep apnea (OSA) serving as a well-established risk factor. However, emerging evidence implicates additional sleep disturbances—including central sleep apnea, insomnia, and restless legs syndrome—in AF pathogenesis and progression. Despite compelling observational data, interventional studies evaluating the impact of sleep disorder treatment on AF outcomes have yielded mixed results. Although continuous positive airway pressure therapy in patients with OSA mitigates AF recurrence, randomized controlled trials have yet to confirm a definitive causal benefit. This review synthesizes epidemiological, mechanistic, and interventional data linking sleep disorders to AF.